This webinar has already taken place. However, you can watch a recording of it below.
00:00:00 – Dawn Van Dam, One Million Solutions in Health: Opening and TEC Opportunity
00:07:40 – Dawn Van Dam, One Million Solutions in Health: Webinar and Speaker Introductions
00:11:45 – Josh Kangas, Quantitative Medicine: Improving Research Productivity using Core™
00:27:00 – Jorrit Hornberg, Lundbeck: Example of Predictive QSAR Modeling as Part of Exploratory Toxicology
00:47:50 – Richard Brennan, Sanofi: Applying an Active Machine Learning Process to Build Predictive Models of In Vivo Toxicity from ToxCast Screening Data
01:11:45 – Questions and Answers
In developing drugs, it is important to optimize for a specific set of characteristics. Many of these characteristics can be measured experimentally after purchasing or synthesizing compounds. The high cost and time required to synthesize novel compounds makes it very important to rapidly identify optimal structures.
Quantitative Medicine’s Computational Research Engine (CoRE™) is designed to optimize.
CoRE™ utilizes sophisticated machine learning techniques to direct synthesis efforts to efficiently identify optimal structures. In previous studies, CoRE™ has been shown to reduce the required synthesis by 40-90%, depending on the specific task. What would that sort of impact have on your synthesis project?
In this webinar, you will have an opportunity to learn about the CoRE™ technology utilized in some state-of-the-art studies with speakers from Sanofi, Lundbeck and Quantitative Medicine.
Additionally, One Million Solutions in Health is offering an opportunity to further evaluate the CoRE™ technology. Biopharmaceutical companies or academic research centers are encouraged to participate in a free trial of this Active Machine Learning tool by joining the Technology Evaluation Consortium™ (TEC).
Along with the case studies, the webinar provides information on this opportunity to join the TEC, which brings together biopharmaceutical companies, other researchers, and technology providers to evaluate and validate new technologies.
CONTACT US TODAY TO JOIN THIS FREE OPPORTUNITY –> EVALUATE A NEW WAY TO ACCELERATE DRUG DEVELOPMENT.
Jorrit Hornberg, PhD
Head of In Vitro Studies
Richard Brennan, PhD
Josh Kangas PhD
Chief Science Officer
Dawn Van Dam
President and CEO
One Million Solutions in Health